381 related articles for article (PubMed ID: 34763718)
1. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
[TBL] [Abstract][Full Text] [Related]
3. Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.
Priebe V; Sartori G; Napoli S; Chung EYL; Cascione L; Kwee I; Arribas AJ; Mensah AA; Rinaldi A; Ponzoni M; Zucca E; Rossi D; Efremov D; Lenz G; Thome M; Bertoni F
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32679859
[TBL] [Abstract][Full Text] [Related]
4. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.
Nogai H; Wenzel SS; Hailfinger S; Grau M; Kaergel E; Seitz V; Wollert-Wulf B; Pfeifer M; Wolf A; Frick M; Dietze K; Madle H; Tzankov A; Hummel M; Dörken B; Scheidereit C; Janz M; Lenz P; Thome M; Lenz G
Blood; 2013 Sep; 122(13):2242-50. PubMed ID: 23869088
[TBL] [Abstract][Full Text] [Related]
5. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
[TBL] [Abstract][Full Text] [Related]
6. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
Davis RE; Brown KD; Siebenlist U; Staudt LM
J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
[TBL] [Abstract][Full Text] [Related]
7. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L
Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164
[TBL] [Abstract][Full Text] [Related]
8. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
11. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.
Thompson RC; Herscovitch M; Zhao I; Ford TJ; Gilmore TD
J Biol Chem; 2011 Jan; 286(3):1675-82. PubMed ID: 20947507
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma.
Bonetti P; Testoni M; Scandurra M; Ponzoni M; Piva R; Mensah AA; Rinaldi A; Kwee I; Tibiletti MG; Iqbal J; Greiner TC; Chan WC; Gaidano G; Piris MA; Cavalli F; Zucca E; Inghirami G; Bertoni F
Blood; 2013 Sep; 122(13):2233-41. PubMed ID: 23926301
[TBL] [Abstract][Full Text] [Related]
13. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
14. Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.
Gamboa-Cedeño AM; Castillo M; Xiao W; Waldmann TA; Ranuncolo SM
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1437-1448. PubMed ID: 30941572
[TBL] [Abstract][Full Text] [Related]
15. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
[TBL] [Abstract][Full Text] [Related]
16. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
17. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.
Pulvino M; Liang Y; Oleksyn D; DeRan M; Van Pelt E; Shapiro J; Sanz I; Chen L; Zhao J
Blood; 2012 Aug; 120(8):1668-77. PubMed ID: 22791293
[TBL] [Abstract][Full Text] [Related]
19. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
20. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
